<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172950</url>
  </required_header>
  <id_info>
    <org_study_id>CSL627_3001</org_study_id>
    <secondary_id>2013-003262-13</secondary_id>
    <nct_id>NCT02172950</nct_id>
  </id_info>
  <brief_title>An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A</brief_title>
  <official_title>A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII‑SingleChain, CSL627) in Subjects With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, open-label, phase 3 extension study will investigate the safety and
      efficacy of rVIII‑SingleChain for prophylaxis and on‑demand treatment of bleeding episodes in
      at least 200 previously treated patients (PTPs) with severe congenital hemophilia A and
      previous exposure to FVIII products who achieve at least 100 exposure days (EDs) to
      rVIII-SingleChain in this study, as well as in at least 50 previously untreated patients
      (PUPs) with no previous exposure to any FVIII product who achieve at least 50 EDs to
      rVIII-SingleChain in this study. A substudy (open to both PTPs and PUPs) will investigate the
      use of rVIII-SingleChain in surgery. A substudy (open to PUPs who develop an inhibitor to
      rVIII-SingleChain) will investigate the use of rVIII-SingleChain in immune tolerance
      induction (ITI) therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 13, 2014</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of inhibitor formation to FVIII in PTPs with 100 EDs to rVIII-SingleChain</measure>
    <time_frame>At the closest visit after 100 EDs (up to 5 years).</time_frame>
    <description>Number of PTPs (with 100 EDs to rVIII-SingleChain) with inhibitor formation to FVIII</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of high-titer inhibitor formation to FVIII in at least 50 PUPs with at least 50 EDs of rVIII-SingleChain</measure>
    <time_frame>At the closest visit after 50 EDs (up to 5 years).</time_frame>
    <description>Number of PUPs (with at least 50 EDs of rVIII-SingleChain) with high-titer inhibitor formation to FVIII. High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success for major bleeding episodes in PUPs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of major bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of &quot;excellent&quot; or &quot;good&quot; on the investigator's clinical assessment of hemostatic efficacy 4-point scale &quot;excellent, good, moderate or poor/no response&quot;. Major bleeding episodes are defined as bleeding episodes for which a subject is required to seek treatment at the hemophilia center or that threatens the subject's life or loss of limb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized spontaneous bleeding rate in PUPs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The annualized spontaneous bleeding rate for PUPs taking prophylaxis and on-demand treatment regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment success in PTPs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of &quot;excellent&quot; or &quot;good&quot; on the investigator's clinical assessment of hemostatic efficacy 4-point scale &quot;excellent, good, moderate or poor/no response&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate in PTPs and PUPs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The annualized bleeding rate for PTPs and PUPs taking prophylaxis and on-demand treatment regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of bleeding episodes requiring 1, 2, 3, or &gt; 3 injections of rVIII-SingleChain to achieve hemostasis in PTPs and PUPs</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rVIII-SingleChain in PTPs and PUPs - injections</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The number of rVIII-SingleChain injections per month and per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rVIII-SingleChain in PTPs and PUPs - IU/kg</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>rVIII-SingleChain consumption (IU/kg) per month and per year, and per event during prophylaxis, on-demand, and surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic efficacy of rVIII-SingleChain for PTPs and PUPs who undergo surgery</measure>
    <time_frame>From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)</time_frame>
    <description>The investigator will rate the efficacy of the rVIII-SingleChain treatment during surgery based on a hemostatic efficacy four point rating scale of &quot;excellent, good, moderate or poor/no response&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of inhibitor formation to FVIII after 10 EDs and after 50 EDs in PTPs</measure>
    <time_frame>After 10 and after 50 exposure days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of PTPs and PUPs developing antibodies against rVIII-SingleChain</measure>
    <time_frame>PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of PTPs and PUPs developing antibodies to Chinese hamster ovary (CHO) proteins</measure>
    <time_frame>PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of high-titer inhibitor formation to FVIII in PUPs after 10 EDs with rVIII-SingleChain</measure>
    <time_frame>At the closest visit after 10 EDs</time_frame>
    <description>Number of PUPs (after 10 EDs of rVIII-SingleChain) with high-titer inhibitor formation to FVIII. High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of low-titer inhibitor formation to FVIII in PUPs</measure>
    <time_frame>At the closest visit after 10 and after 50 EDs (up to 5 years)</time_frame>
    <description>Number of PUPs (after 10 and 50 EDs of rVIII-SingleChain) with low-titer inhibitor formation to FVIII. Low-titer inhibitor is defined as an inhibitor titer of less than 5 Bethesda units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of total inhibitor formation to FVIII in PUPs</measure>
    <time_frame>At the closest visit after 10 and after 50 EDs (up to 5 years)</time_frame>
    <description>Number of PUPs (after 10 and 50 EDs of rVIII-SingleChain) with inhibitor formation (both low- and high-titer inhibitors) to FVIII.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success for non-major bleeding episodes in PUPs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of &quot;excellent&quot; or &quot;good&quot; on the investigator's clinical assessment of hemostatic efficacy 4-point scale &quot;excellent, good, moderate or poor/no response&quot;. Non-major bleeding episodes are those not requiring treatment at the hemophilia center or not threatening subject's life or loss of limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of PUPs with clinically significant abnormal vital signs values after first rVIII-SingleChain injection</measure>
    <time_frame>At 1, 2, 3, and 6 hours after first rVIII-SingleChain injection</time_frame>
    <description>Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of PUPs with treatment-emergent clinically significant abnormal vital signs values</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Severe Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Previously treated patients (PTPs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII‑SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previously untreated patients (PUPs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII‑SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVIII‑SingleChain</intervention_name>
    <description>Recombinant single-chain coagulation factor VIII</description>
    <arm_group_label>Previously treated patients (PTPs)</arm_group_label>
    <arm_group_label>Previously untreated patients (PUPs)</arm_group_label>
    <other_name>CSL627</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        PTPs:

          -  Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII
             activity levels &lt; 1%) and who participated in a previous CSL-sponsored clinical study
             with rVIII-SingleChain.

          -  Males 0 to &lt;65 years age who have been diagnosed with severe congenital hemophilia A
             (FVIII activity levels &lt; 1%), who have at least 50 EDs to any FVIII product, and who
             are not currently enrolled in a CSL-sponsored clinical study with rVIII-SingleChain.

        PUPs:

          -  Males 0 to &lt;18 years of who have been diagnosed with severe congenital hemophilia A
             (FVIII activity levels &lt; 1%)

          -  No prior exposure to any Factor VIII product (with the exception of short-term use of
             blood products).

        ITI substudy:

          -  PUPs who have developed a confirmed inhibitor to rVIII-SingleChain in the main study.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to rVIII‑SingleChain or to any excipients of
             rVIII‑SingleChain or Chinese hamster ovary (CHO) proteins.

          -  Currently receiving a therapy not permitted during the study.

          -  Serum creatinine &gt; 2 x upper limit of normal, alanine aminotransferase or aspartate
             aminotransferase &gt; 5 x upper limit of normal at Screening (if specified)

          -  Any first-order family (eg, siblings) history of FVIII inhibitors

          -  For PTPs not rolling over directly from a CSL-sponsored clinical study with
             rVIII-SingleChain: any history of or current FVIII inhibitors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study Site 8400155</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 8400213</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 8400241</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 8400118</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 8400116</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 8400184</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 8400204</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>8400834</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 8400240</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 8400041</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 8400154</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 0360014</name>
      <address>
        <city>Melbourne</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 0360028</name>
      <address>
        <city>Nedlands</city>
        <zip>WA 6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 0360031</name>
      <address>
        <city>Perth</city>
        <zip>WA 6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 0400012</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 0400003</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 0400001</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 0400002</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 1240022</name>
      <address>
        <city>Saint John</city>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2030017</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2500015</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2500017</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2500028</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2500018</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2500002</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2680001</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2760034</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2760032</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2760084</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2760091</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2760087</name>
      <address>
        <city>Giessen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 2760066</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 2760086</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Study Site 3480007</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 3720002</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 3800023</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 3920031</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 3920029</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 3920064</name>
      <address>
        <city>Okayama</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 3920033</name>
      <address>
        <city>Saitama</city>
        <zip>339-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 3920025</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 4220007</name>
      <address>
        <city>Beirut</city>
        <zip>165191</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 4580001</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 5280006</name>
      <address>
        <city>Amsterdam Zuidoost</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 5280008</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 5280007</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 6080001</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6080002</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6160013</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6160038</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6160035</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-301</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6160014</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6200002</name>
      <address>
        <city>Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6200001</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 6420030</name>
      <address>
        <city>Bucharest</city>
        <zip>011026</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6420034</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Study Site 6420037</name>
      <address>
        <city>Timisoara</city>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7100001</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 7240008</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7240021</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 7240007</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site 7240023</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7560010</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7640001</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7640005</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7640002</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7640004</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 7640003</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 8040007</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 8040005</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site 8260008</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

